← Leaderboards
C. Conrad Johnston
Indiana Univ-Purdue Univ At Indianapolis
$0
Attributed
$0
Total exposure
7
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$0 · 7
By mechanism
M01$0 · 7
Top collaborators
No co-investigators on record.
Most similar at Indiana Univ-Purdue Univ At Indianapolis
Same institution · by research overlap
- Linda A Dimeglio$12,449,185
- Munro Peacock$2,764,841
- David B Burr$11,269,068
- Charles H Turner$5,408,679
- Michael J Econs$17,934,951
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchOsteoporosisSkeletal Disorder ChemotherapyFemaleBone DensityDrug Screening /EvaluationHuman Therapy EvaluationWomen'S HealthPostmenopausePhysiologic Bone ResorptionBone MetabolismBone FracturePlacebosSex HormonesDrug Adverse EffectDiphosphonateLongitudinal Animal StudyMenopauseOral AdministrationRacial /Ethnic DifferenceSomatotropinVertebraeEstrogen Inhibitor
Grant awards (49)
ORAL ALENDRONATE SODIUM IN OSTEOPOROSIS IN POST MENOPAUSAL WOMEN$0
M01 · FY2002 · RR
SEX STEROIDS IN AGE RELATED BONE LOSS$0
M01 · FY2002 · RR
DOUBLE BLIND RANDOMIZED PLACEBO CONTROLLED PARALLEL GROUP MULTICENTER STUDY$0
M01 · FY2002 · RR
RALOXIFENE HCL AND PLACEBO IN PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSALS$0
M01 · FY2002 · RR
IBANDRONATE DURING 3 YEARS TREATMENT FOR OSTEOPOROSIS$0
M01 · FY2002 · RR
ROLE OF SEX STEROIDS IN AGE RELATED BONE LOSS--RACE AND SEX DIFFERENCES$0
M01 · FY2002 · RR
DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY ON EFFICACY OF IBANDRONATE$0
M01 · FY2002 · RR
SEX STEROIDS IN AGE RELATED BONE LOSS$0
M01 · FY2001 · RR
DOUBLE BLIND RANDOMIZED PLACEBO CONTROLLED PARALLEL GROUP MULTICENTER STUDY$0
M01 · FY2001 · RR
RALOXIFENE HCL AND PLACEBO IN PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSALS$0
M01 · FY2001 · RR
IBANDRONATE DURING 3 YEARS TREATMENT FOR OSTEOPOROSIS$0
M01 · FY2001 · RR
ROLE OF SEX STEROIDS IN AGE RELATED BONE LOSS--RACE AND SEX DIFFERENCES$0
M01 · FY2001 · RR
DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY ON EFFICACY OF IBANDRONATE$0
M01 · FY2001 · RR
ORAL ALENDRONATE SODIUM IN OSTEOPOROSIS IN POST MENOPAUSAL WOMEN$0
M01 · FY2001 · RR
RALOXIFENE HCL AND PLACEBO IN PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSALS$0
M01 · FY2000 · RR
IBANDRONATE DURING 3 YEARS TREATMENT FOR OSTEOPOROSIS$0
M01 · FY2000 · RR
IBANDRONATE DURING 3 YEARS TREATMENT FOR OSTEOPOROSIS$0
M01 · FY2000 · RR
IBANDRONATE DURING 3 YEARS TREATMENT FOR OSTEOPOROSIS$0
M01 · FY2000 · RR
IBANDRONATE DURING 3 YEARS TREATMENT FOR OSTEOPOROSIS$0
M01 · FY2000 · RR
IBANDRONATE DURING 3 YEARS TREATMENT FOR OSTEOPOROSIS$0
M01 · FY2000 · RR
ROLE OF SEX STEROIDS IN AGE RELATED BONE LOSS--RACE AND SEX DIFFERENCES$0
M01 · FY2000 · RR
ROLE OF SEX STEROIDS IN AGE RELATED BONE LOSS--RACE AND SEX DIFFERENCES$0
M01 · FY2000 · RR
ROLE OF SEX STEROIDS IN AGE RELATED BONE LOSS--RACE AND SEX DIFFERENCES$0
M01 · FY2000 · RR
ROLE OF SEX STEROIDS IN AGE RELATED BONE LOSS--RACE AND SEX DIFFERENCES$0
M01 · FY2000 · RR
ROLE OF SEX STEROIDS IN AGE RELATED BONE LOSS--RACE AND SEX DIFFERENCES$0
M01 · FY2000 · RR
DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY ON EFFICACY OF IBANDRONATE$0
M01 · FY2000 · RR
DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY ON EFFICACY OF IBANDRONATE$0
M01 · FY2000 · RR
DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY ON EFFICACY OF IBANDRONATE$0
M01 · FY2000 · RR
DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY ON EFFICACY OF IBANDRONATE$0
M01 · FY2000 · RR
DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY ON EFFICACY OF IBANDRONATE$0
M01 · FY2000 · RR
SEX STEROIDS IN AGE RELATED BONE LOSS$0
M01 · FY2000 · RR
ORAL ALENDRONATE SODIUM IN OSTEOPOROSIS IN POST MENOPAUSAL WOMEN$0
M01 · FY2000 · RR
ORAL ALENDRONATE SODIUM IN OSTEOPOROSIS IN POST MENOPAUSAL WOMEN$0
M01 · FY2000 · RR
ORAL ALENDRONATE SODIUM IN OSTEOPOROSIS IN POST MENOPAUSAL WOMEN$0
M01 · FY2000 · RR
ORAL ALENDRONATE SODIUM IN OSTEOPOROSIS IN POST MENOPAUSAL WOMEN$0
M01 · FY2000 · RR
ORAL ALENDRONATE SODIUM IN OSTEOPOROSIS IN POST MENOPAUSAL WOMEN$0
M01 · FY2000 · RR
SEX STEROIDS IN AGE RELATED BONE LOSS$0
M01 · FY2000 · RR
SEX STEROIDS IN AGE RELATED BONE LOSS$0
M01 · FY2000 · RR
SEX STEROIDS IN AGE RELATED BONE LOSS$0
M01 · FY2000 · RR
SEX STEROIDS IN AGE RELATED BONE LOSS$0
M01 · FY2000 · RR
DOUBLE BLIND RANDOMIZED PLACEBO CONTROLLED PARALLEL GROUP MULTICENTER STUDY$0
M01 · FY2000 · RR
DOUBLE BLIND RANDOMIZED PLACEBO CONTROLLED PARALLEL GROUP MULTICENTER STUDY$0
M01 · FY2000 · RR
DOUBLE BLIND RANDOMIZED PLACEBO CONTROLLED PARALLEL GROUP MULTICENTER STUDY$0
M01 · FY2000 · RR
DOUBLE BLIND RANDOMIZED PLACEBO CONTROLLED PARALLEL GROUP MULTICENTER STUDY$0
M01 · FY2000 · RR
DOUBLE BLIND RANDOMIZED PLACEBO CONTROLLED PARALLEL GROUP MULTICENTER STUDY$0
M01 · FY2000 · RR
RALOXIFENE HCL AND PLACEBO IN PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSALS$0
M01 · FY2000 · RR
RALOXIFENE HCL AND PLACEBO IN PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSALS$0
M01 · FY2000 · RR
RALOXIFENE HCL AND PLACEBO IN PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSALS$0
M01 · FY2000 · RR
RALOXIFENE HCL AND PLACEBO IN PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSALS$0
M01 · FY2000 · RR